AKBA — Akebia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $213.79m
- $201.97m
- $194.62m
- 32
- 51
- 65
- 47
Annual cashflow statement for Akebia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -280 | -383 | -283 | -92.6 | -51.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 89.3 | 253 | 100 | -7.3 | 11.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -106 | -13.7 | -108 | -11 | -20.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -257 | -110 | -253 | -73.2 | -23.4 |
| Capital Expenditures | -6.66 | -0.317 | -0.059 | -0.114 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 218 | -39.7 | 40 | 0 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 211 | -40 | 39.9 | -0.114 | 0 |
| Financing Cash Flow Items | — | — | 44.8 | 40 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 89 | 232 | 134 | 14.6 | -25.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 42.7 | 81.3 | -79.3 | -58.7 | -48.6 |